MapLight Therapeutics Closes Oversubscribed $225 Million Series C
Reston – November 3, 2023 – Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapies to improve the lives of people with brain disorders, on its oversubscribed $225 million Series C financing. Lawyers Christian Plaza, Matthew Schwee and David Brinton led the Cooley team advising MapLight.
The financing round included new investors – Novo Holdings, 5AM Ventures, Cowen Healthcare Investments and others – along with MapLight’s existing syndicate. Proceeds from the financing will be used to advance ML-007C-MA, a novel M1/M4 muscarinic agonist agent combined with a precision-matched peripheral muscarinic antagonist, into phase 2 trials for schizophrenia and Alzheimer’s disease psychosis in 2024, as well as enabling continued progress on MapLight’s other pipeline programs.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.